Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PRX-105 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| PRX-105 | DRUG | Sterile solution for intravenous injection |
PRX-105 is an investigational small molecule being developed for organophosphate exposure, a condition that can result from contact with certain chemicals used in pesticides and nerve agents. It is currently in early clinical development, with a completed Phase 1 microdose study.
PRX-105 is being developed by Protalix BioTherapeutics, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PLX. The company is conducting clinical research to evaluate the safety and tolerability of this investigational drug.
PRX-105 is in Phase 1 clinical development. A Phase 1 microdose study has been completed, and the drug remains investigational. It has not been approved by regulatory authorities and is still undergoing clinical evaluation for organophosphate exposure.
PRX-105 has one completed clinical trial, identified as NCT01093859, titled "An Exploratory Phase 1 Microdose Study of PRX-105." This early Phase 1 study enrolled 10 participants and was an uncontrolled, non-randomized, open-label trial focused on organophosphate exposure.
PRX-105 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. A Phase 1 microdose study has been completed, but the drug has not yet received regulatory approval for the treatment of organophosphate exposure.